Current and future treatment options for cutaneous lupus erythematosus

Bibliography

• Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011;64(5):849-58
   PubMed Web of Science ®Google Scholar
• Hale ED, Treharne GJ, Norton Y, et al. ’Concealing the evidence’: the importance of appearance concerns for patients with systemic lupus erythematosus. Lupus 2006;15(8):532-40
   Google Scholar
• Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 2009;145(3):249-53
   PubMedGoogle Scholar
• Tebbe B. Clinical course and prognosis of cutaneous lupus erythematosus. Clin Dermatol 2004;22(2):121-4
   Google Scholar
• Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981;4(4):471-5
   PubMed Web of Science ®Google Scholar
• Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10(6):365-81
   PubMed Web of Science ®Google Scholar
• Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988;31(8):1007-13
   PubMedGoogle Scholar
• Prystowsky SD, Gilliam JN. Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus. Arch Dermatol 1975;111(11):1448-52
   Google Scholar
• Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982;118(6):412-16
   PubMedGoogle Scholar
• Maize JCJr, Costner M. Tumid lupus erythematosus: a form of lupus erythematosus. Arch Dermatol 2010;146(4):451
   Google Scholar
• Fraga J, Garcia-Diez A. Lupus erythematosus panniculitis. Dermatol Clin 2008;26(4):453-63
   Google Scholar
• Hedrich CM, Fiebig B, Hauck FH, et al. Chilblain lupus erythematosus-a review of literature. Clin Rheumatol 2008;27(10):1341
   Google Scholar
• James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007;16(6):401-9
   PubMed Web of Science ®Google Scholar
• Barbhaiya M, Costenbader KH. Ultraviolet radiation and systemic lupus erythematosus. Lupus 2014;23(6):588-95
   Google Scholar
• Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004;50(9):3045-6
   Google Scholar
• Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011;64(1):37-48
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Gilaberte Y, Philips N. Mechanistic insights in the use of a Polypodium leucotomos extract as an oral and topical photoprotective agent. Photochem Photobiol Sci 2010;9(4):559-63
   Google Scholar
• Breithaupt AD, Jacob SE. Subacute cutaneous lupus erythematosus: a case report of Polypodium leucotomos as an adjuvant therapy. Cutis 2012;89(4):183-4
   Google Scholar
• Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2008;24(5):260-7
   Google Scholar
• Heine G, Lahl A, Muller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol 2010;163(4):863-5
   Google Scholar
• Cutillas-Marco E, Marquina-Vila A, Grant W, et al. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus 2014
   PubMed Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125(5):889-94
   PubMed Web of Science ®Google Scholar
• Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008;144(2):173-80
   Google Scholar
• Roenigk HHJr, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980;25(3):281-5
   PubMed Web of Science ®Google Scholar
• Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011;65(1):54-64; e1-2
   Google Scholar
• Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009;34(7):776-80
   Google Scholar
• Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007;20(4):160-74
   PubMed Web of Science ®Google Scholar
• Lester RS, Burnham TK, Fine G, Murray K. Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine. Arch Dermatol 1967;96(1):1-10
   Google Scholar
• Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011;147(11):1261-7
   PubMedGoogle Scholar
• Chasset F, Frances C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. J Am Acad Dermatol 2015
   Google Scholar
• Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;5 Suppl 1:S11-15
   Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48(11):3207-11
   PubMed Web of Science ®Google Scholar
• Wenzel J, Brahler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005;153(1):157-62
   PubMed Web of Science ®Google Scholar
• Newton RC, Jorizzo JL, Solomon ARJr, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986;122(2):170-6
   Google Scholar
• Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992;127(5):513-18
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988;124(6):897-902
   Google Scholar
• Lindskov R, Reymann et al. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986;172(4):214-17
   Google Scholar
• Ludgate MW, Greig DE. Bullous systemic lupus erythematosus responding to dapsone. Australas J Dermatol 2008;49(2):91-3
   Google Scholar
• Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45(3):420-34
   PubMed Web of Science ®Google Scholar
• Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 2007;20(4):206-15
   PubMedGoogle Scholar
• Ashinoff R, Werth VP, Franks AGJr. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988;19(5 Pt 2):961-5
   Google Scholar
• Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991;127(4):515-22
   PubMedGoogle Scholar
• Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002;138(12):1616-18
   PubMedGoogle Scholar
• Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001;45(1):142-4
   Google Scholar
• Kreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007;156(6):1321-7
   Google Scholar
• Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365(20):1886-95
   PubMed Web of Science ®Google Scholar
• Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol 2011;65(4):717-21
   PubMed Web of Science ®Google Scholar
• Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005;153(2):254-73
   PubMed Web of Science ®Google Scholar
• Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983;108(4):461-6
   Google Scholar
• Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000;39(3):218-22
   Google Scholar
• Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005;14(6):434-9
   Google Scholar
• Gambini D, Carrera C, Passoni E, et al. Thalidomide treatment for hypertrophic cutaneous lupus erythematosus. J Dermatolog Treat 2004;15(6):365-71
   PubMedGoogle Scholar
• Zara G, Ermani M, Rondinone R, et al. Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry 2008;79(11):1258-61
   PubMed Web of Science ®Google Scholar
• Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity 2005;38(7):549-55
   PubMed Web of Science ®Google Scholar
• Genereau T, Chosidow O, Danel C, et al. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 1999;135(9):1124-5
   Google Scholar
• Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 2005;85(6):545-7
   Google Scholar
• Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004;15(1):46-50
   PubMedGoogle Scholar
• McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 1996;5(4):269-74
   Google Scholar
• Sanders CJ, Lam HY, Bruijnzeel-Koomen CA, et al. UV hardening therapy: a novel intervention in patients with photosensitive cutaneous lupus erythematosus. J Am Acad Dermatol 2006;54(3):479-86
   Google Scholar
• Kim A, Chong BF. Photosensitivity in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2013;29(1):4-11
   Google Scholar
• Pavel S. Light therapy (with UVA-1) for SLE patients: is it a good or bad idea? Rheumatology 2006;45(6):653-5
   Google Scholar
• Okon L, Rosenbach M, Krathen M, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. J Am Acad Dermatol 2014;70(3):583-4
   PubMed Web of Science ®Google Scholar
• Cortes-Hernandez J, Avila G, Vilardell-Tarres M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012;14(6):R265
   Google Scholar
• Eisenberg R. Update on rituximab. Ann Rheum Dis 2005;64(Suppl 4):iv55-7
   Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Ann Rheum 2010;62(1):222-33
   Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Ann Rheum 2012;64(4):1215-26
   Google Scholar
• Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature. Lupus 2013;22(9):932-9
   PubMed Web of Science ®Google Scholar
• Risselada AP, Kallenberg CG. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology 2006;45(7):915-16
   Google Scholar
• Uthman I, Taher A, Abbas O, et al. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 2008;216(3):257-9
   Google Scholar
• Kieu V, O’Brien T, Yap LM, et al. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australas J Dermatol 2009;50(3):202-6
   Google Scholar
• McArdle A, Baker JF. A case of “refractory” lupus erythematosus profundus responsive to rituximab [case report]. Clin Rheum 2009;28(6):745-6
   Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-31
   PubMed Web of Science ®Google Scholar
• Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013;368(16):1528-35
   PubMed Web of Science ®Google Scholar
• Tanasescu C, Balanescu E, Balanescu P, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med 2010;21(3):202-7
   PubMed Web of Science ®Google Scholar
• Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus 2012;21(9):1007-10
   PubMed Web of Science ®Google Scholar
• Dahl C, Johansen C, Kragballe K, Olesen AB. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol 2013;93(3):368-9
   PubMed Web of Science ®Google Scholar
• Varada S, Gottlieb AB, Merola JF, et al. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol 2015;72(2):253-60
   PubMed Web of Science ®Google Scholar
• De Souza A, Strober BE, Merola JF, et al. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. JDD 2012;11(10):1224-6
   PubMed Web of Science ®Google Scholar
• Rao V, Gordon C. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. Immunotherapy 2014;6(11):1165-75
   PubMed Web of Science ®Google Scholar
• Al Rayes H, Touma Z. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther 2014;8:2303-10
   PubMed Web of Science ®Google Scholar
• Wenzel J, Tuting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol 2007;16(5):454-63
   Google Scholar
• Narwal R, Roskos LK, Robbie GJ. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet 2013;52(11):1017-27
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Ducreux J, Houssiau FA. Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford) 2014;53(8):1369-76
   PubMed Web of Science ®Google Scholar
• Gul U, Gonul M, Cakmak SK, et al. A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. Adv Ther 2006;23(5):787-92
   Web of Science ®Google Scholar
• Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52(10):3073-8
   Google Scholar
• Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012;166(3):616-23
   PubMed Web of Science ®Google Scholar
• Suess A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. Int J Dermatol 2008;47(1):83-6
   Google Scholar
• Wollina U, Looks A. Extracorporeal photochemotherapy in cutaneous lupus erythematosus. JEADV 1999;13(2):127-30
   Google Scholar
• Wulf HC, Ullman S. Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream. Arch Dermatol 2007;143(12):1589-90
   Google Scholar
• Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010;10(4):587-604
   PubMed Web of Science ®Google Scholar
• Ito T, Seo N, Yagi H, et al. Unique therapeutic effects of the Japanese-Chinese herbal medicine, Sairei-to, on Th1/Th2 cytokines balance of the autoimmunity of MRL/lpr mice. J Dermatol Sci 2002;28(3):198-210
   PubMed Web of Science ®Google Scholar